Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir and Lenacapavir injection tolerability in healthy adults
NCT06970223Phase 1Active, not recruiting
- Sponsor
- ViiV Healthcare
- Start
- Apr 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of cabotegravir and lenacapavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Percentage of participants reporting very acceptable or totally acceptable local reactions at 7 days. Started Apr 2025; status: active, not recruiting.
02
Drugs
cabotegravirlenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06970223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970223.